Commission Implementing Regulation (EU) 2017/1531 of 7 September 2017 renewing the approval of the active substance imazamox, as a candidate for substitution, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011 (Text with EEA relevance. )
Common Name, Identification Numbers | IUPAC Name | Purity | Date of approval | Expiration of approval | Specific provisions |
---|---|---|---|---|---|
2-[(RS)-4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl]-5-methoxymethylnicotinic acid |
|
(1) in Part A, entry 41 on imazamox is deleted; (2) in Part E, the following entry is added: Further details on identity and specification of active substance are provided in the review report. Number Common Name, Identification Numbers IUPAC Name Purity Date of approval Expiration of approval Specific provisions "8 imazamox CAS No 114311-32-9 CIPAC No 619 2-[(RS)-4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl]-5-methoxymethylnicotinic acid ≥ 950 g/kg The impurity cyanide ion (CN – ) shall not exceed 5 mg/kg in the technical material.1 November 2017 31 October 2024 For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on imazamox, and in particular Appendices I and II thereto, shall be taken into account. In this overall assessment Member States shall pay particular attention to: the protection of consumers; the protection of aquatic plants and of non-target terrestrial plants; the protection of groundwater, when the substance is applied in regions with vulnerable soil and/or climatic conditions.
Conditions of authorisation shall include risk mitigation measures and monitoring programs shall be initiated to verify potential groundwater contamination from imazamox and metabolites CL 312622 and CL 354825 in vulnerable zones, where appropriate." ----------------------Further details on identity and specification of active substance are provided in the review report.